| Company/Division name | List Biotherapeutics, Inc., |
| Parent company | List Biological Laboratories, Inc. |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 201 |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 125 |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | Fishers |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Microbiome anticancer drug |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Other, US industry trend to contract manufacturing |
